| Symbol | VYGR |
|---|---|
| Name | VOYAGER THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 75 SIDNEY STREET, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 857 259-5340 |
| Fax | — |
| — | |
| Website | https://www.voyagertherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001640266 |
| Description | Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The companys gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Voyager Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003626 <b>Size:</b> 10 KB
Read moreVoyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
Read moreDirector SCANGOS GEORGE A 🟢 acquired 30.0K shares (1 derivative) of Voyager Therapeutics, Inc. (VYGR) at $3.43 Transaction Date: Jun 09, 2026 | Filing ID: 072934
Read moreDirector MACKEY CATHERINE J 🟢 acquired 30.0K shares (1 derivative) of Voyager Therapeutics, Inc. (VYGR) at $3.43 Transaction Date: Jun 09, 2026 | Filing ID: 072927
Read moreDirector Hyman Steven 🟢 acquired 30.0K shares (1 derivative) of Voyager Therapeutics, Inc. (VYGR) at $3.43 Transaction Date: Jun 09, 2026 | Filing ID: 072926
Read moreDirector Vitale Nancy 🟢 acquired 30.0K shares (1 derivative) of Voyager Therapeutics, Inc. (VYGR) at $3.43 Transaction Date: Jun 09, 2026 | Filing ID: 072924
Read moreDirector Higgins Michael J 🟢 acquired 30.0K shares (1 derivative) of Voyager Therapeutics, Inc. (VYGR) at $3.43 Transaction Date: Jun 09, 2026 | Filing ID: 072923
Read moreDirector Onyia Jude 🟢 acquired 30.0K shares (1 derivative) of Voyager Therapeutics, Inc. (VYGR) at $3.43 Transaction Date: Jun 09, 2026 | Filing ID: 072922
Read moreDirector GERAGHTY JAMES A 🟢 acquired 30.0K shares (1 derivative) of Voyager Therapeutics, Inc. (VYGR) at $3.43 Transaction Date: Jun 09, 2026 | Filing ID: 072921
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07764146 | An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzhei… | Phase1 | Alzheimer s Disease | Not_Yet_Recruiting | 2026-08-24 | 2029-04-28 | ClinicalTrials.gov |
| NCT05490225 | Access Cannulation Trial II | Na | Dialysis; Complications | Recruiting | 2025-04-23 | 2027-03-25 | ClinicalTrials.gov |
| NCT06874621 | VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Do… | Phase1 | Alzheimer's Disease (AD) | Active_Not_Recruiting | 2025-03-03 | 2027-05-01 | ClinicalTrials.gov |
| NCT04885114 | Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting H… | Phase1 | Huntington Disease | Withdrawn | 2021-07-30 | 2024-12-30 | ClinicalTrials.gov |
| NCT00231946 | ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease D… | Phase3 | Alzheimer's Disease | Completed | 2005-09-01 | — | ClinicalTrials.gov |
| NCT00076440 | Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN)… | Phase2 | Alzheimer Disease | Completed | 2003-12-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00063310 | ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestig… | Phase2 | Alzheimer Disease | Completed | 2003-03-01 | 2006-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Anti-AAV9 Total Antibody (TAb) Assay | Other | Phase PHASE1 | Alzheimer s Disease | NOT_YET_RECRUITING | NCT07764146 |
| VY1706 High Dose | Other | Phase PHASE1 | Alzheimer s Disease | NOT_YET_RECRUITING | NCT07764146 |
| VY1706 Mid dose | Other | Phase PHASE1 | Alzheimer s Disease | NOT_YET_RECRUITING | NCT07764146 |
| VY1706 Low dose | Other | Phase PHASE1 | Alzheimer s Disease | NOT_YET_RECRUITING | NCT07764146 |
| VP4896 | Other | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT00231946 |
| VP4896 | Other | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT00231946 |
| VP4896 | Other | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT00231946 |
| Leuprolide acetate | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00076440 |
| Leuprolide acetate | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00076440 |
| Leuprolide acetate | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00063310 |
| Leuprolide acetate | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00063310 |
| Intraparenchymal rAAV1 - (mi)RNA HTT | Other | Phase PHASE1 | Huntington Disease | WITHDRAWN | NCT04885114 |
| VenaSure | Other | Approved | Dialysis; Complications | RECRUITING | NCT05490225 |
| VenaSure | Other | Approved | Dialysis; Complications | RECRUITING | NCT05490225 |
| Placebo Comparator | Other | Phase PHASE1 | Alzheimer's Disease (AD) | ACTIVE_NOT_RECRUITING | NCT06874621 |
| VY7523 | Other | Phase PHASE1 | Alzheimer's Disease (AD) | ACTIVE_NOT_RECRUITING | NCT06874621 |
| VP4896 | DRUG | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT00231946 |
| Leuprolide acetate | DRUG | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00076440 |
| Leuprolide acetate | DRUG | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00063310 |